Good News, Bad News For Novartis’ Oral MS Drug, But REMS Could Help

Tysabri’s REMS could prove to be a model for drugs with serious safety signals.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet